Patents by Inventor Graham Edmund Kelly
Graham Edmund Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120003337Abstract: Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.Type: ApplicationFiled: April 1, 2011Publication date: January 5, 2012Applicant: NOVOGEN RESEARCH PTY LTD.Inventor: Graham Edmund Kelly
-
Publication number: 20110305782Abstract: This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen analogues, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example. The invention describes a method of improving the health of a human by administering to the human a health supplementing amount of a phyto-oestrogen selected from genistein, daidzein formononentin and/or biochanin A. A health supplement comprising a health supplementary amount of a phyto-oestrogen selected from genisten daidzein formononentin and/or biochanin A, is also described. Preferably, the supplement also comprises at least one dietary suitable excipient, diluent, carrier or food, and may be in the form of a tablet or capsule, for example. Ideally, the phyto-oestrogen is extracted from red clover or from soya, although any source rich in isoflavones may also be used.Type: ApplicationFiled: June 17, 2011Publication date: December 15, 2011Applicant: NOVOGEN RESEARCH PTY LTD.Inventor: Graham Edmund Kelly
-
Publication number: 20110212989Abstract: Therapeutic method of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H or RACO wherein Ra is C1-10alkyl or an amino acid, R2 is H, OH or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c) or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (f) and B is (g) where R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, anType: ApplicationFiled: May 6, 2011Publication date: September 1, 2011Applicant: NOVOGEN RESEARCH PTY LTDInventors: Graham Edmund KELLY, George Eustace Joannou
-
Patent number: 7915308Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC wherType: GrantFiled: July 22, 2008Date of Patent: March 29, 2011Assignee: Novogen Research Pty LtdInventors: Graham Edmund Kelly, George Eustace Joannou
-
Patent number: 7906554Abstract: This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention further relates to compounds, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention.Type: GrantFiled: October 2, 2003Date of Patent: March 15, 2011Assignee: Novogen Research Pty LtdInventor: Graham Edmund Kelly
-
Patent number: 7776843Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of bone injuries. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1.3)(1.6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1.3)(1.6) glucan and non-glucan components.Type: GrantFiled: August 4, 2006Date of Patent: August 17, 2010Assignee: Novogen Research Pty. Ltd.Inventor: Graham Edmund Kelly
-
Patent number: 7714151Abstract: Aminated isoflavonoid synthesized by aminating the 4-keto group of isoflavanone and isoflavanone ring systems, pharmaceutical compositions containing same and uses thereof as therapeutic agents.Type: GrantFiled: November 3, 2003Date of Patent: May 11, 2010Assignee: Novogen Research Pty LtdInventors: Graham Edmund Kelly, Andrew Heaton, Jane Faragalla, John Bremner
-
Patent number: 7648968Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of dermal ulcers. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.Type: GrantFiled: August 4, 2006Date of Patent: January 19, 2010Assignee: Novogen Research Pty. Ltd.Inventor: Graham Edmund Kelly
-
Patent number: 7622575Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of connective tissue injuries. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.Type: GrantFiled: August 4, 2006Date of Patent: November 24, 2009Assignee: Novogen Research Pty. Ltd.Inventor: Graham Edmund Kelly
-
Publication number: 20090233999Abstract: Isoflavone compounds and analogues thereof, compositions containing same and therapeutic methods of treatment involving same are described.Type: ApplicationFiled: November 6, 2008Publication date: September 17, 2009Applicant: NOVOGEN RESEARCH PTY LTDInventors: ANDREW HEATON, NARESH KUMAR, GRAHAM EDMUND KELLY, ALAN HUSBAND
-
Patent number: 7488494Abstract: Isoflavone compounds are described and recommended as therapeutic agents. Exemplified and preferred compounds are (a). Indications show compounds have good competitive binding to estrogen receptors.Type: GrantFiled: November 7, 2003Date of Patent: February 10, 2009Assignee: Novogen Research Pty Ltd.Inventors: Andrew Heaton, Naresh Kumar, Graham Edmund Kelly, Alan Husband
-
Publication number: 20080287528Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC wherType: ApplicationFiled: July 22, 2008Publication date: November 20, 2008Applicant: Novogen Research PTY LimitedInventors: Graham Edmund KELLY, George Eustace Joannou
-
Patent number: 7419998Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H.Type: GrantFiled: December 28, 2004Date of Patent: September 2, 2008Assignee: Novogen Research Pty LtdInventors: Graham Edmund Kelly, George Eustace Joannou
-
Patent number: 7312344Abstract: A compound of the general formula (I) or (II) wherein X is O, NR4 or S and R1-R8 are as defined in the specificationType: GrantFiled: March 8, 2002Date of Patent: December 25, 2007Assignee: Novogen Research Pty LimitedInventors: Andrew Heaton, Graham Edmund Kelly, Naresh Kumar
-
Patent number: 7202273Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2Rc where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CORC whereType: GrantFiled: June 21, 2002Date of Patent: April 10, 2007Assignee: Novogen Research Pty LtdInventors: Graham Edmund Kelly, George Eustace Joannou
-
Patent number: 7045155Abstract: Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.Type: GrantFiled: October 21, 2002Date of Patent: May 16, 2006Assignee: Novogen Research Pty Ltd.Inventor: Graham Edmund Kelly
-
Patent number: 6987098Abstract: Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.Type: GrantFiled: July 2, 2003Date of Patent: January 17, 2006Assignee: Novogen Research Pty. Ltd.Inventor: Graham Edmund Kelly
-
Publication number: 20040170713Abstract: This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen analogues, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example. The invention describes a method of improving the health of a human by administering to the human a health supplementing amount of a phyto-oestrogen selected from genistein, daidzein formononentin and/or biochanin A. A health supplement comprising a health supplementary amount of a phyto-oestrogen selected from genisten daidzein formononentin and/or biochanin A, is also described. Preferably, the supplement also comprises at least one dietary suitable excipient, diluent, carrier or food, and may be in the form of a tablet or capsule, for example. Ideally, the phyto-oestrogen is extracted from red clover or from soya, although any source rich in isoflavones may also be used.Type: ApplicationFiled: March 11, 2004Publication date: September 2, 2004Applicant: Novogen Research Pty Ltd.Inventor: Graham Edmund Kelly
-
Publication number: 20040152761Abstract: A compound of the general formula (I) or (II) wherein X is O, NR4 or S and R1-R8 are as defined in the specification.Type: ApplicationFiled: March 8, 2004Publication date: August 5, 2004Inventors: Andrew Heaton, Graham Edmund Kelly, Naresh Kumar
-
Patent number: RE40792Abstract: Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.Type: GrantFiled: May 19, 1993Date of Patent: June 23, 2009Assignee: Novogen Research Pty LtdInventor: Graham Edmund Kelly